Table 2 Selective clinical trials of AR signaling inhibitors

From: Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

Drug

Target

Condition

Status

Phase

NCT identifier

Degarelix

GnRHR

PCa

Completed

3

NCT00451958

Degarelix

GnRHR

PCa

Completed

3

NCT01071915

Degarelix

GnRHR

PCa

Completed

3

NCT02015871

Relugolix

GnRHR

PCa

Recruiting

3

NCT05050084

Relugolix

GnRHR

PCa

Completed

3

NCT03085095

Abarelix

GnRHR

PCa

Completed

3

NCT00841113

Leuprolide

GnRHR

PCa

Completed

4

NCT00220194

Leuprolide

GnRHR

PCa

Recruiting

3

NCT04914195

Goserelin

GnRHR

PCa

Completed

3

NCT00439751

Goserelin

GnRHR

PCa

Not yet recruiting

4

NCT03971110

Triptorelin

GnRHR

PCa

Completed

3

NCT01715129

Triptorelin

GnRHR

PCa

Completed

3

NCT00104741

Histrelin

GnRHR

Metastatic PCa

Recruiting

2/3

NCT04787744

Histrelin

GnRHR

PCa

Completed

3

NCT01697384

Buserelin

GnRHR

PCa

Completed

3

NCT00003653

Buserelin

GnRHR

PCa

Recruiting

3

NCT05050084

Enzalutamide

AR

CRPC

Completed

3

NCT00974311

Enzalutamide

AR

mCRPC

Completed

4

NCT02116582

Enzalutamide

AR

mCRPC

Completed

4

NCT02485691

Apalutamide

AR

PCa

Completed

2

NCT01790126

Apalutamide

AR

Nonmetastatic CRPC

Recruiting

3

NCT04108208

Darolutamide

AR

PCa

Not yet recruiting

3

NCT02799602

Darolutamide

AR

Nonmetastatic CRPC

Completed

3

NCT02200614

ARV-110

AR

mCRPC

Recruiting

1/2

NCT03888612

Abiraterone

CYP17A1

mCRPC

Completed

3

NCT04056754

Abiraterone

CYP17A1

mCRPC

Completed

3

NCT00887198

Abiraterone

CYP17A1

mCRPC

Completed

3

NCT02111577

Seviteronel

CYP17A1

CRPC

Completed

2

NCT02445976

Orteronel

CYP17A1

mCRPC

Completed

3

NCT01193257

Galeterone

CYP17A1

CRPC

Completed

2

NCT01709734